【病毒外文文獻(xiàn)】2014 Human neutralizing mAbs against Middle East respiratory syndrome coronavirus (MERS-CoV)

the distillery SciBX Science Business eXchange Copyright 2014 Nature Publishing Group 1 This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Human neutralizing mAbs against Middle East respiratory syndrome coronavirus MERS CoV Human neutralizing mAbs against MERS CoV could aid the development of new therapeutics to treat or prevent infection A screen of a single chain variable domain fragment scFv phage library yielded seven unique fragments that bind to the MERS CoV spike protein In a nonhuman primate cell line the most potent human mAbs generated from the identified scFvs neutralized the MERS CoV with IC 50 values ranging from 1 25 to 2 mg mL Next steps could include optimizing the lead neutralizing mAb and evaluating it in models of MERS CoV infection SciBX 7 21 doi 10 1038 scibx 2014 629 Published online May 29 2014 Patent and licensing status unavailable Tang X C et al Proc Natl Acad Sci USA published online April 28 2014 doi 10 1073 pnas 1402074111 Contact Wayne A Marasco Dana Farber Cancer Institute Boston Mass e mail wayne marasco dfci harvard edu